Iingcali ze-Epidemiologists ziqikelela ukuba bangaphezulu kwe-160 lezigidi zabantu kwihlabathi liphela abaye baphola kwi-COVID-19

Iingcali ze-Epidemiologists ziqikelela ukuba bangaphezulu kwe-160 lezigidi zabantu kwihlabathi liphela abaye baphola kwi-COVID-19.Abo baye bachacha banezihlandlo ezisezantsi ezothusayo zosulelo oluphindaphindiweyo, izigulo okanye ukufa.Oku kungakhuseleki kusulelo lwangaphambili lukhusela abantu abaninzi abangenalo isitofu sokugonya okwangoku.
Kwangoko kule nyanga, uMbutho wezeMpilo weHlabathi ukhuphe uhlaziyo lwesayensi oluchaza ukuba uninzi lwabantu abalulama kwi-COVID-19 baya kuba nempendulo eyomeleleyo yokhuselo lomzimba.Okubalulekileyo, bagqibe kwelokuba kwiiveki ezi-4 zosulelo, i-90% ukuya kwi-99% yabantu abachacha kwi-COVID-19 baya kuphuhlisa izilwa-buhlungu ezinokubonwa.Ukongeza, bagqiba-ngokuthathela ingqalelo ixesha elilinganiselweyo lokujonga iimeko-impendulo yokhuselo lomzimba yahlala yomelele kangangeenyanga ezi-6 ukuya kwezi-8 emva kosulelo.
Olu hlaziyo luvumelana nengxelo ye-NIH ngoJanuwari ka-2021: Bangaphezulu kwe-95% yabantu abaye baphola kwi-COVID-19 banempendulo yokuzikhusela komzimba enenkumbulo engapheliyo yentsholongwane ukuya kuthi ga kwiinyanga ezisi-8 emva kokosuleleka.AmaZiko ezeMpilo eSizwe aphinde achaza ukuba ezi ziphumo "zinika ithemba" lokuba abantu abagonyiweyo baya kukhula okufanayo kugonyo oluhlala luhleli.
Ke kutheni sinikela ingqalelo engaka kugonyo olubangelwa sisitofu-kwinjongo yethu yokufezekisa ukungakhuseleki komhlambi, iitshekhi zethu ekuhambeni, imisebenzi kawonke-wonke okanye yabucala, okanye ukusetyenziswa kweemaski-ngelixa sityeshela ukungagungqi kwendalo?Ngaba akufanelanga ukuba abo banokugonywa kwendalo nabo bakwazi ukuphinda baqalise imisebenzi “eqhelekileyo”?
Izazinzulu ezininzi ziye zafumanisa ukuba umngcipheko wokosuleleka kwakhona uncitshisiwe, kwaye ukulaliswa esibhedlele kunye nokufa ngenxa yokwasulelwa kwakhona kuphantsi kakhulu.Kwizifundo ezithandathu ezibandakanya phantse isigidi esi-1 sabantu eziqhutywe yi-United States, i-United Kingdom, i-Denmark, i-Ostriya, i-Qatar, kunye ne-United States Marine Corps, ukuncitshiswa kwe-COVID-19 yokosuleleka kwakhona ukusuka kwi-82% ukuya kwi-95%.Uphononongo lwase-Austrian lukwafumanise ukuba ukuphindaphindwa kosulelo lwe-COVID-19 kubangele kuphela abantu aba-5 kwi-14,840 (0.03%) ukuba bangeniswe esibhedlele, kwaye umntu omnye kwabayi-14,840 (0.01%) basweleka.
Ukongeza, idatha yamva nje yase-US ekhutshwe emva kwesibhengezo se-NIH ngoJanuwari yafumanisa ukuba izilwa-buhlungu ezikhuselayo zinokuhlala ukuya kuthi ga kwiinyanga ezili-10 emva kosulelo.
Njengoko abenzi bomgaqo-nkqubo wezempilo yoluntu benciphisa ukungakhuseleki kwabo kwisimo sokugonywa, iingxoxo azikuhoyi ubukhulu becala ukuntsonkotha kwenkqubo yomzimba yokuzikhusela.Kukho inani leengxelo zophando ezikhuthazayo ezibonisa ukuba iiseli zegazi emzimbeni wethu, ezibizwa ngokuba “ziiseli ze-B kunye neeseli ze-T”, zinegalelo kukhuseleko lweeseli emva kwe-COVID-19.Ukuba ukungakhuseleki kwe-SARS-CoV-2 kuyafana nolunye usulelo olubi lwe-coronavirus, njengokungakhuseleki kwe-SARS-CoV-1, ke olu khuselo lunokuhlala iminyaka eli-17 ubuncinci.Nangona kunjalo, iimvavanyo ezilinganisa ukhuseleko lweeseli zintsonkothile kwaye ziyabiza, nto leyo eyenza kube nzima ukuyifumana kwaye ithintele ukusetyenziswa kwazo kunyango lwesiqhelo okanye kuvavanyo lwempilo yoluntu.
I-FDA igunyazise iimvavanyo ezininzi ze-antibody.Njengalo naluphi na uvavanyo, zifuna iindleko zemali kunye nexesha lokufumana iziphumo, kwaye ukusebenza kovavanyo ngalunye kunomahluko obalulekileyo kwinto emele i-antibody eqinisekileyo.Umahluko ophambili ngowokuba ezinye iimvavanyo zifumanisa kuphela izilwa-buhlungu ezifunyenwe emva kosulelo lwendalo, izilwa-buhlungu “ze-N”, ngelixa ezinye zingenako ukwahlula phakathi kwezilwa-buhlungu zendalo okanye ezenziwe ngogonyo, izilwa-buhlungu “ze-S”.Oogqirha kunye nezigulana kufuneka banike ingqwalasela koku kwaye babuze ukuba zeziphi izilwa-buhlungu oluvavanywa ngokwenene.
Kwiveki ephelileyo, nge-19 kaMeyi, i-FDA ikhuphe incwadana yeendaba yokhuseleko eluntwini isithi nangona uvavanyo lwe-antibody lwe-SARS-CoV-2 ludlala indima ebalulekileyo ekuchongeni abantu abakhe bachanabeka kwintsholongwane ye-SARS-CoV-2 kwaye banokuba sele bephuhlile ukungagungqi. Impendulo yesenzo, uvavanyo lwe-antibody akufuneki lusetyenziswe ukumisela ukungakhuseleki okanye ukhuseleko kwi-COVID-19.Kulungile?
Nangona kubalulekile ukunikela ingqalelo kwisigidimi, kuyabhida.I-FDA ayizange ibonelele ngedatha kwisilumkiso kwaye ishiye abo baye balunyukiswa bengaqinisekanga ukuba kutheni uvavanyo lwe-antibody lungasetyenziselwa ukumisela ukungakhuseleki okanye ukhuseleko kwi-COVID-19.Ingxelo ye-FDA iqhube yathi uvavanyo lwe-antibody kufuneka lusetyenziswe ngabo banamava kuvavanyo lwe-antibody.akukho ncedo.
Njengakwimiba emininzi yempendulo karhulumente wobumbano kwi-COVID-19, amagqabantshintshi e-FDA asemva kwesayensi.Ngenxa yokuba ama-90% ukuya kuma-99% abantu abachacha kwi-COVID-19 baya kuphuhlisa izilwa-buhlungu ezinokubonwa, oogqirha banokusebenzisa uvavanyo oluchanekileyo ukwazisa abantu ngomngcipheko wabo.Sinokuxelela izigulana ukuba abantu abaye baphola kwi-COVID-19 banokhuseleko oluluqilima, olunokubakhusela ekosulelweni kwakhona, kwizifo, esibhedlele, nasekufeni.Enyanisweni, olu khuselo luyafana okanye lungcono kunogonyo olubangelwa kukugonya.Ngamafutshane, abantu abachacha kusulelo lwangaphambili okanye abanezilwa-buhlungu ezinokubonwa kufuneka bathathwe njengabakhuselweyo, ngokufanayo nabantu abagonyiweyo.
Ukujonga kwikamva, abaqulunqi bomgaqo-nkqubo kufuneka babandakanye ukungaguquki kwendalo njengoko kumiselwe luvavanyo oluchanekileyo noluthembekileyo lwe-antibody okanye amaxwebhu osulelo lwangaphambili (i-PCR ngaphambili okanye uvavanyo lwe-antigen) njengobungqina obufanayo bokugonywa njengogonyo.Olu khuselo lomzimba lufanele lubenewonga lasekuhlaleni elifanayo nogonyo olubangelwa sisitofu sokugonya.Umgaqo-nkqubo onjalo uya kunciphisa kakhulu ukuxhalaba kunye nokwandisa amathuba okuhamba, imisebenzi, ukutyelela intsapho, njl. kwaye ujoyine umkhosi ogonyiweyo.
UJeffrey Klausner, MD, MPH, uprofesa weklinikhi yeyeza lokukhusela kwi-Keck School of Medicine kwiYunivesithi yaseSouth California, eLos Angeles, kunye nowayesakuba ligosa lezonyango kwiZiko loLawulo lweSifo kunye noThintelo.UNowa Kojima, MD, ngugqirha ohlala kumayeza angaphakathi kwiYunivesithi yaseCalifornia, eLos Angeles.
U-Klausner ungumlawuli wezonyango wenkampani yokuvavanya i-Curative kwaye wachaza iifizi zeDanaher, Roche, Cepheid, Abbott kunye neSigaba seSayensi.Ngaphambili uye wafumana inkxaso-mali evela kwi-NIH, i-CDC, kunye nabavelisi bovavanyo lwabucala kunye neenkampani ezixuba amayeza ukuphanda iindlela ezintsha zokubona kunye nokunyanga izifo ezosulelayo.
Izinto ezikule webhusayithi zezesalathiso kuphela kwaye azithathi ndawo yeengcebiso zonyango, ukuxilongwa okanye unyango olunikezelwa ngababoneleli bezempilo abaqeqeshiweyo.© 2021 MedPage Namhlanje, LLC.onke Amalungelo Agciniwe.IMedpage Namhlanje lolunye lweempawu zorhwebo ezibhalisiweyo zeMedPage Namhlanje, LLC kwaye ayinakusetyenziswa ngabantu besithathu ngaphandle kwemvume ecacileyo.